Method of administering a methylene blue-curcumin analog for the treatment of alzheimer's disease

• US 8,609,652 B2
• Filed: 11/30/2010
• Issued: 12/17/2013
• Est. Priority Date: 01/26/2009
• Status: Active Grant

• Current Assignee: DePuy Synthes Products LLC (Johnson & Johnson)
• Original Assignee: DePuy Synthes Products LLC (Johnson & Johnson)
• Inventors: DiMauro, Thomas M.
• Primary Examiner(s): Gembeh, Shirley V
• Application Number:
  US12/956,306
• Publication Number:
  US 20110130392A1
• Time in Patent Office: 1,113 Days
• Field of Search: 514/224.8, 544/37
• US Class Current: 514/224.8
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: C07D 279/28 with other substituents attached to the ring system

Abstract

A method of administering a methylene blue-curcumin hybrid useful in treating or preventing Alzheimer'"'"'s Disease.

Claims

1. A method of treating Alzheimer'"'"'s Disease in a patient, comprising the step of administering a diphenolic phenazathionium compound to the patient.

2. The method of claim 1 wherein the diphenolic phenazathionium is selected from the group consisting of:

a) 2,6-bis(4′

,4″

dihydroxyphenyl)3,7-bis(dimethylamino)-phenazathionium chloride, and

b) 2,6-bis(4′

,4″

dihydroxy-3′

3″

dimethoxy phenyl)3,7-bis(dimethylamino)-phenazathionium chloride.

3. The method of claim 1 wherein the compound is administered orally via a pill or a tablet.

4. The method of claim 1 wherein the compound is administered intranasally.

5. The method of claim 1 wherein the compound is administered iontophoretically.

6. The method of claim 1 wherein the compound is administered transmucosally.